Surface plasmon resonance P-selectin inhibition
Serum samples collected and analyzed after administration of a single IV dose of inclacumab showed that mean P-selectin inhibition was nearly complete (defined as > 90%) for up to 12 weeks post-dose in both cohorts with a mean (range) of P-selectin inhibition at week 12 of 94.2% (65.4–100%) in cohort 1 and 99.4% (96.3–100%) in cohort 2. Subsequently, mean P-selectin inhibition appeared to decrease gradually in both cohorts. At week 29, mean (range) P-selectin inhibition was 6.38% (0–17.8%) in cohort 1 and 35.4% (0–100%) in cohort 2 (Fig. 